U.S. markets closed

Conformis, Inc. (CFMS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.1800+0.0400 (+3.51%)
At close: 4:00PM EDT
1.1700 -0.01 (-0.85%)
After hours: 05:16PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close1.1400
Open1.1100
Bid1.1200 x 1400
Ask1.1700 x 900
Day's Range1.1100 - 1.1800
52 Week Range0.6020 - 1.4900
Volume1,242,145
Avg. Volume2,548,773
Market Cap215.322M
Beta (5Y Monthly)1.25
PE Ratio (TTM)N/A
EPS (TTM)-0.3020
Earnings DateAug 03, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Conformis, Inc. to Present at the Oppenheimer MedTech, Tools & Diagnostics Summit
    GlobeNewswire

    Conformis, Inc. to Present at the Oppenheimer MedTech, Tools & Diagnostics Summit

    BILLERICA, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, will present at the Oppenheimer MedTech, Tools & Diagnostics Summit. A webcast of the virtual presentation will be made available on the day of the summit, Wednesday, May 26, 2021. Conformis management will also be available for one-on-one meetings throughout the summit. For more information about the conference or to schedule a one-on-one meeting with management, please contact your Oppenheimer representative or Conformis Investor Relations at ir@conformis.com and (781) 374-5598. The replay of the webcast of the presentation will be archived on Conformis' website for 30 days following the presentation under "Events and Presentations" in the Investors section of the Conformis website at ir.conformis.com. About Conformis, Inc. Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit and conform to each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints. For more information, visit www.comformis.com. To receive future releases in e-mail alerts, sign up at ir.conformis.com. CONTACT: Investor Contact: ir@conformis.com (781) 374-5598

  • Conformis, Inc. to Present at the Canaccord Genuity Musculoskeletal Conference
    GlobeNewswire

    Conformis, Inc. to Present at the Canaccord Genuity Musculoskeletal Conference

    BILLERICA, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will present at the Canaccord Genuity Musculoskeletal Conference. The virtual presentation is scheduled for Thursday, May 20, 2021 at 10:30 a.m. ET. A live webcast of the presentation will be available at https://wsw.com/webcast/canaccord54/cfms/2442655. Conformis management will also be available for one-on-one meetings throughout the conference. For more information about the conference or to schedule a one-on-one meeting with management, please contact your Canaccord representative or Conformis Investor Relations at ir@conformis.com and (781) 374-5598. The live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Conformis website at ir.conformis.com. The replay of the webcast will be archived on Conformis' website for 30 days following the presentation. About Conformis, Inc. Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit and conform to each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints. For more information, visit www.comformis.com. To receive future releases in e-mail alerts, sign up at ir.conformis.com. CONTACT: Investor Contact: ir@conformis.com (781) 374-5598

  • MedTech Round Up: Update On Products By Conformis, Medtronic, Orthofix, Neovasc
    Benzinga

    MedTech Round Up: Update On Products By Conformis, Medtronic, Orthofix, Neovasc

    The FDA has given 510(k) clearance for Conformis Inc's (NASDAQ: CFMS) Identity Imprint Knee Replacement System, available in both cruciate-retaining (CR) and posterior stabilized (PS) versions. Identity Imprint utilizes a proprietary 3-dimensional "best-fit" algorithm to select the implant that most closely meets the geometric and anatomic requirements of the patient based on the patient's computed tomography scans. Price Action: CFMS shares are trading 6.95% higher at $0.90 during the market trading session on the last check Monday. Medtronic plc (NYSE: MDT) has announced the U.S. commercial launch of the SonarMed airway monitoring system, a pediatric monitor to check endotracheal tube (ETT) obstruction and verify position in real-time. SonarMed, which Medtronic acquired in December 2020, specializes in developing solutions that increase patient safety while significantly decreasing healthcare costs. Price Action: MDT shares are up 0.43% at $127.24 during the market trading session on the last check Monday. The FDA has given 510(k) clearance to Orthofix Medical Inc's (NASDAQ: OFIX) OrthoNext digital platform, a software tool for deformity analysis and preoperative planning for pediatric orthopedic procedures. Developed specifically for use with the JuniOrtho Plating System, the OrthoNext digital platform software enables the surgeon to plan the osteotomy position accurately to visualize the implant concerning the anatomy. The company has initiated its U.S. and European full market launch of the JuniOrtho Plating System. Price Action: OFIX shares are down 4.05% at $42.37 during the market trading session on the last check Monday. Neovasc Inc (NASDAQ: NVCN) has enrolled the first patient in the COSIMA trial investigating the company's Reducer for the treatment of Microvascular Angina. The study will enroll up to 144 patients across multiple centers in Germany. The primary endpoint of the study is the change in CCS angina class, a measure of chest pain severity and limitation, by two or more classes. The Reducer is CE-marked in the European Union to treat refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle. Price Action: NVCN shares are down 3.2% at $0.83 during the market trading session on the last check Monday. See Benzinga's FDA Calendar See more from BenzingaClick here for options trades from BenzingaHeron Stock Trading Higher After Q1 Earnings, Ahead Of HTX-011 Decision Scheduled This WeekTaysha Gene Therapies' Rett Syndrome Candidate Shows Encouraging Action In Animal Studies, Human Trial To Start By 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.